Formatech program donates fill/finish for RegeneRx's MS candidate

Formatech will donate aseptic fill and finish services for one lot of a RegeneRx Biopharmaceuticals' drug candidate to treat cardiovascular and central nervous system diseases. The donation is part of the Massachusetts contract manufacturer's Fillanthropy Program, in which the company makes a monthly fill/finish donation to a company whose product is beginning human clinical trials.

The RegeneRx Biopharmaceuticals candidate, RGN-352, is an injectable formulation of a novel therapeutic peptide known as Thymosin Beta 4, targeted at conditions best treated via systemic delivery. RegeneRx is planning early-phase trials of RGN-352 as a treatment for multiple sclerosis.

Via the Fillanthropy Program, launched last August, Formatech made a similar donation recently to Tracon for its TRC102 small-molecule inhibitor of DNA base excision repair. The program has also awarded fills to GeoVax Labs for an HIV/AIDS vaccine candidate, to KAI Pharmaceuticals for its secondary hyperparathyroidism treatment, and to ViroMed for a vaccine targeting breast cancer.

- see the announcement

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.